Literature DB >> 23213009

Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.

David S Goldberg1, Amanda Camp, Alvaro Martinez-Camacho, Lisa Forman, Brett Fortune, K Rajender Reddy.   

Abstract

Patients with primary sclerosing cholangitis (PSC) are at increased risk for bacterial cholangitis because of biliary strictures and bile stasis. A subset of PSC patients suffer from repeated episodes of bacterial cholangitis, which can lead to frequent hospitalizations and impaired quality of life. Although waitlist candidates with PSC and bacterial cholangitis frequently receive exception points and/or are referred for living donor transplantation, the impact of bacterial cholangitis on waitlist mortality is unknown. We performed a retrospective cohort study of all adult waitlist candidates with PSC who were listed for initial transplantation between February 27, 2002 and June 1, 2012 at the University of Pennsylvania and the University of Colorado-Denver. During this period, 171 PSC patients were waitlisted for initial transplantation. Before waitlisting, 38.6% (66/171) of the patients had a history of bacterial cholangitis, whereas 28.0% (44/157) of the patients with at least 1 Model for End-Stage Liver Disease update experienced cholangitis on the waitlist. During follow-up, 30 patients (17.5%) were removed from the waitlist for death or clinical deterioration, with 46.7% (14/30) developing cholangiocarcinoma. Overall, 12 of the 82 waitlist candidates (14.6%) who ever had an episode of cholangitis were removed for death or clinical deterioration, whereas 18 of the 89 candidates (20.2%) without cholangitis were removed (P = 0.34 for a comparison of the 2 groups). No patients were removed because of bacterial cholangitis. In multivariate competing-risk models, a history of bacterial cholangitis was not associated with an increased risk of waitlist removal for death or clinical deterioration (subhazard ratio = 0.67, 95% confidence interval = 0.65-0.70, P < 0.001). In summary, waitlist transplant candidates with PSC and bacterial cholangitis do not have an increased risk of waitlist mortality. The data call into question the systematic granting of exception points or referral for living donor transplantation due to a perceived risk of increased waitlist mortality.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23213009      PMCID: PMC3600057          DOI: 10.1002/lt.23587

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

1.  Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.

Authors:  Richard B Freeman; Robert G Gish; Ann Harper; Gary L Davis; John Vierling; Leslie Lieblein; Goran Klintmalm; Jamie Blazek; Robert Hunter; Jeffrey Punch
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

2.  Model for end-stage liver disease (MELD) exception for bacterial cholangitis.

Authors:  Gregory J Gores; Robert G Gish; Roshan Shrestha; Russell H Wiesner
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

Review 3.  Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.

Authors:  Cynthia Levy; Keith D Lindor
Journal:  Semin Liver Dis       Date:  2006-02       Impact factor: 6.115

4.  Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list.

Authors:  Bjørn Brandsaeter; Ulrika Broomé; Helena Isoniemi; Styrbjörn Friman; Bent Hansen; Erik Schrumpf; Antti Oksanen; Bo-Göran Ericzon; Krister Höckerstedt; Heikki Mäkisalo; Rolf Olsson; Michael Olausson; Preben Kirkegaard; Kristian Bjøro
Journal:  Liver Transpl       Date:  2003-09       Impact factor: 5.799

5.  Clinicopathologic features of the syndrome of primary sclerosing cholangitis.

Authors:  R H Wiesner; N F LaRusso
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

6.  Deaths on the liver transplant waiting list: an analysis of competing risks.

Authors:  W Ray Kim; Terry M Therneau; Joanne T Benson; Walter K Kremers; Charles B Rosen; Gregory J Gores; E Rolland Dickson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

7.  Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy.

Authors:  B Brandsaeter; Helena Isoniemi; Ulrika Broomé; Michael Olausson; Lars Bäckman; Bent Hansen; Erik Schrumpf; Antti Oksanen; Bo-Göran Ericzon; Krister Höckerstedt; Heikki Mäkisalo; Preben Kirkegaard; Styrbjörn Friman; Kristian Bjøro
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

8.  Analysis of longitudinal data to evaluate a policy change.

Authors:  Benjamin French; Patrick J Heagerty
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

9.  Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.

Authors:  R H Wiesner; P M Grambsch; E R Dickson; J Ludwig; R L MacCarty; E B Hunter; T R Fleming; L D Fisher; S J Beaver; N F LaRusso
Journal:  Hepatology       Date:  1989-10       Impact factor: 17.425

Review 10.  A note on competing risks in survival data analysis.

Authors:  J M Satagopan; L Ben-Porat; M Berwick; M Robson; D Kutler; A D Auerbach
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more
  12 in total

Review 1.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

2.  Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.

Authors:  Yan-Hua Lai; Wei-Dong Duan; Qiang Yu; Sheng Ye; Nian-Jun Xiao; Dong-Xin Zhang; Zhi-Qiang Huang; Zhan-Yu Yang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.

Authors:  Jawad Ahmad
Journal:  Hepatol Int       Date:  2018-11-14       Impact factor: 6.047

Review 4.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

5.  Standardizing MELD Exceptions: Current Challenges and Future Directions.

Authors:  David S Goldberg; Kim M Olthoff
Journal:  Curr Transplant Rep       Date:  2014-12-01

Review 6.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

Review 7.  Cholangitis: Diagnosis, Treatment and Prognosis.

Authors:  Amir Houshang Mohammad Alizadeh
Journal:  J Clin Transl Hepatol       Date:  2017-09-07

Review 8.  Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Konstantinos H Katsanos; Epameinondas V Tsianos; Dimitrios K Christodoulou
Journal:  Gastroenterology Res       Date:  2018-04-07

9.  Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway.

Authors:  Ina M Andersen; Bjarte Fosby; Kirsten M Boberg; Ole P F Clausen; Peter Jebsen; Espen Melum; Pål D Line; Aksel Foss; Erik Schrumpf; Tom H Karlsen
Journal:  Transplant Direct       Date:  2015-10-19

Review 10.  Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.

Authors:  Sho Hasegawa; Masato Yoneda; Yusuke Kurita; Asako Nogami; Yasushi Honda; Kunihiro Hosono; Atsushi Nakajima
Journal:  Drugs       Date:  2021-06-17       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.